@BikeRieder Avatar @BikeRieder BikeRieder🇨🇭

BikeRieder🇨🇭 posts on X about $arwr, novartis, ceo, biotech the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [-----] #

Followers Line Chart

CreatorRank: [---------] #

CreatorRank Line Chart

Social Influence

Social category influence stocks 10.08% finance 5.88% countries 5.04% social networks 2.52% currencies 2.52% exchanges 0.84% fashion brands 0.84%

Social topic influence $arwr #20, novartis 3.36%, ceo 2.52%, biotech 2.52%, discord 2.52%, balance sheet 2.52%, approved 1.68%, the first 1.68%, in the 1.68%, switzerland 1.68%

Top accounts mentioned or mentioned by @arrowheadpharma @pawcio2009 @sonichedgefund @hall8jack @bioboyscout @biohazard3737 @bionerd51 @zac1967 @honegger @srfnews @biomannn @varroanalytics @yaireinhorn @ej23ny @bowtiedbiotech @gline @rnairevq1h4v @drmakaryfda @megynkelly @bioman944918473

Top assets mentioned Arrowhead Research Corporation (ARWR) Novartis AG (NVS) Sarepta Therapeutics, Inc. (SRPT) DOSE (DOSE) Alnylam Pharmaceuticals, Inc. (ALNY) BlackRock Inc (BLK) Goldman Sachs (GS) Sanofi (SNY) Ionis Pharmaceuticals, Inc. Common Stock (IONS)

Top Social Posts

Top posts by engagements in the last [--] hours

"$ARWR Just a little reminder PR [--] days ago: PASADENA Calif.(BUSINESS WIRE)Nov. [--] [----] Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1 also called SRP-1003 an investigational RNA interference (RNAi) therapeutic for the treatment of type [--] myotonic dystrophy (DM1) the most common adult-onset muscular dystrophy. In accordance with the license and collaboration"
X Link 2026-01-23T10:19Z [----] followers, [----] engagements

"$ARWR Just to be clear the MS of $200 million is just earned but NOT received. Must be in tomorrow"
X Link 2026-01-23T15:16Z [----] followers, [----] engagements

"$ARWR STILL no PR about receiving the $200 million milestone payment but a new SEC filing. Doug Ingram CEO of $SRPT will no longer be a Board Member of our company Any implications for the deal Let's speculate"
X Link 2026-01-28T06:07Z [----] followers, [----] engagements

"$ARWR Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration https://www.prnewswire.com/news-releases/longevity-biotech-stocks-surge-as-27-trillion-healthcare-shift-favors-cell-restoration-302674367.html https://www.prnewswire.com/news-releases/longevity-biotech-stocks-surge-as-27-trillion-healthcare-shift-favors-cell-restoration-302674367.html"
X Link 2026-01-30T06:21Z [----] followers, [----] engagements

"$ARWR From partimefriend on discord From Underdiagnosed to Under Control: PlozaSiran and Pharmacists Role in FCS and siRNAi's outlook in general https://www.pharmacytimes.com/view/from-underdiagnosed-to-under-control-plozasiran-and-pharmacists-role-in-fcs https://www.pharmacytimes.com/view/from-underdiagnosed-to-under-control-plozasiran-and-pharmacists-role-in-fcs"
X Link 2026-01-31T08:44Z [----] followers, [----] engagements

"Novartis sales of Leqvio (siRNAi IncliSiran) in 2025: $1.2 billion - blockbuster. About 240'000 patients Novartis preparing the medical system and patients for $ARWR cardio metabolic drugs PlozaSiran (REDEMPLO) ZodaSiran etc etc"
X Link 2026-02-04T07:26Z [----] followers, [----] engagements

"IONS had $6 million revenue with TRYNGOLZA in their first full quarter (Q1/2025. Price is around $600'000 per year monthly dosing $50'000 per injection = [--] patients $ARWR REDEMPLO approved on November 18th [----] at a price of $60'000 per year [--] infections a year. So only about [--] weeks of sales possible. For [--] injection we go our first [---] patients Wonderful start https://twitter.com/i/web/status/2019518697635828064 https://twitter.com/i/web/status/2019518697635828064"
X Link 2026-02-05T21:09Z [----] followers, [----] engagements

"$ARWR Over [---] prescriptions for REDEMPLO have been received from a diverse prescriber base with geographically balanced uptake across the U.S.; Early patient starts fall into three categories: patients transitioning from our Expanded Access Program patients nave to the APOC3 class and patients switching from olezarsen; Patients receiving REDEMPLO include both clinically diagnosed and genetically confirmed FCS with the majority not required to submit genetic testing to gain access; https://twitter.com/i/web/status/2019519092051329475 https://twitter.com/i/web/status/2019519092051329475"
X Link 2026-02-05T21:10Z [----] followers, [----] engagements

"$ARWR Financials for Q1/2025"
X Link 2026-02-05T21:17Z [----] followers, [----] engagements

"$ARWR More and important information about our balance sheet from CFO 💰💰💰 Turning now to the balance sheet. Cash and investments totaled $917 million as of December [--] [----]. Common shares outstanding at quarter end were [-----] million. To be clear the reported cash balance does not include the $200 million that we earned for the DM1 second milestone which was received in January; nor does it include the $50 million anniversary payment that we expect to receive from Sarepta on or before February [--]. Finally and importantly the cash balance of $916 million also does not include the financing"
X Link 2026-02-06T12:32Z [----] followers, [---] engagements

"$ARWR FINALLY the first over $100 but still doesn't validate the PLATFORM COMPANY $ARWR PT raised to $110 at Piper $ARWR PT raised to $110 at Piper"
X Link 2026-01-13T13:21Z [----] followers, [----] engagements

"$ARWR What is good for IONS is great for us. REDEMPLO is safer more effective and much cheaper"
X Link 2026-01-14T12:57Z [----] followers, [----] engagements

"$ARWR News Drug Development [--] Next-Gen Candidates That Could Form the Future of Alzheimers https://www.biospace.com/drug-development/4-next-gen-candidates-that-could-form-the-future-of-alzheimers-treatment https://www.biospace.com/drug-development/4-next-gen-candidates-that-could-form-the-future-of-alzheimers-treatment"
X Link 2026-01-19T13:51Z [----] followers, [----] engagements

"RT @pawcio2009: Look at these fking Canadian morons there was a mass shooting today and they are worried about misidentifying the shooter"
X Link 2026-02-11T05:03Z [----] followers, [--] engagements

"$ARWR Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia https://www.businesswire.com/news/home/20260127479152/en/Arrowhead-Pharmaceuticals-Initiates-Phase-12a-Study-of-ARO-DIMER-PA-the-First-Dual-Functional-RNAi-Therapeutic-for-the-Treatment-of-Mixed-Hyperlipidemia https://www.businesswire.com/news/home/20260127479152/en/Arrowhead-Pharmaceuticals-Initiates-Phase-12a-Study-of-ARO-DIMER-PA-the-First-Dual-Functional-RNAi-Therapeutic-for-the-Treatment-of-Mixed-Hyperlipidemia"
X Link 2026-01-27T12:36Z [----] followers, [----] engagements

"$ARWR Arrowhead is at the forefront of innovation in the RNAi field and were proud of the versatile capabilities of our TRiM platform now including the first-ever clinical candidate that can potentially silence expression of two genes in one RNAi molecule said Chris Anzalone Ph.D. President and CEO at Arrowhead Pharmaceuticals. ARO-DIMER-PA is designed to silence both the PCSK9 and APOC3 genes which together have substantial clinical validation as important targets for reducing LDL-cholesterol triglycerides and total atherogenic lipoproteins. We see ARO-DIMER-PA as having the potential to"
X Link 2026-01-27T12:38Z [----] followers, [---] engagements

"@sonichedgefund @Hall8Jack @Bionerd51 $ARWR To finish the speculation about the $200 million MS from srpt a2b_c2d (Thx) found the important news hidden in the SEC proxy's from [--] days ago. Market knows srpt has some balance sheet problems so our IR should put this info in a PR&@#%#"
X Link 2026-01-29T07:16Z [----] followers, [----] engagements

"RT @zac1967: Nichts knnte @honegger von @srfnews und seine linken Freunde weniger kmmern"
X Link 2026-02-12T12:55Z [----] followers, [--] engagements

"$ARWR Arrowhead Pharmaceuticals to Webcast [----] Fiscal Year End Results on November 26th https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-2024-fiscal-year-end-results https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-2024-fiscal-year-end-results"
X Link 2024-11-05T12:40Z [----] followers, [---] engagements

"$ARWR Months ago since CEO in public happy to hear him personally - first time ever at UBS Zrich He addressed honestly the big question market is waiting for a response: how do you pay for the big pipeline He was quite excited so deal soon with a Swiss giant NDA Nov24. $ARWR ubs presentation credit tadmak: https://t.co/W29qCnZ9Lp $ARWR ubs presentation credit tadmak: https://t.co/W29qCnZ9Lp"
X Link 2024-11-13T06:10Z [----] followers, [----] engagements

"$ARWR Great IDEA Big opportunity to reduce costs So let's stop [--] phase [--] PlozaSiran in patients with sHTG and Dyslipidemia bc our phase [--] in FCS (genetic and clinical diagnosed) patients was very successful My #1 issue with FDA is that it erects unnecessary barriers to innovation (e.g. two replicate phase [--] studies instead of one refusal to accept valid clinical results from other nations etc.). This stops patients from accessing promising therapies & raises prescription drug My #1 issue with FDA is that it erects unnecessary barriers to innovation (e.g. two replicate phase [--] studies instead"
X Link 2024-11-15T09:04Z [----] followers, [----] engagements

"$ARWR Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase [--] Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-data-aha24-palisade-phase https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-data-aha24-palisade-phase"
X Link 2024-11-18T12:43Z [----] followers, [---] engagements

"$ARWR After listening to fireside chat at Jeffries I look forward to hear about a pulmonary platform deal with RAGE MUC5AC and MMP7 in coming weeks. https://ir.arrowheadpharma.com/events-and-presentations https://ir.arrowheadpharma.com/events-and-presentations"
X Link 2024-11-20T09:32Z [----] followers, [----] engagements

"$ARWR RNAi and we are still attractive for partnering Our CEO @ArrowheadPharma was hated by many with this Partnership he will be loved again. If he delivers with a great launch of PlozaSiran next year he will be everybody's darling. Patience payed https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-global-license-and https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-global-license-and"
X Link 2024-11-26T13:00Z [----] followers, [----] engagements

"$ARWR I admit I was never a fan of Sarepta and their DMD-drugs. But to advance ARWR's candidates under this collaboration I see it very positive Our other BP partner's are slow walking partners. SRPT has big interests to go fast"
X Link 2024-11-26T13:34Z [----] followers, [---] engagements

"With [--] cand. deal $ARWR is eligible to receive dev. MS of between $110 mil and $410 mil per program and sales milestone payments of between $500 mil and $700 mil per PROGRAM. ARWR is also eligible to receive tiered royalties on commercial sales up to the low double digits💪💰💰"
X Link 2024-11-26T16:14Z [----] followers, [---] engagements

"$ARWR Verona WI manufac/testing fac. successfully completed requirements to manufacture GMP drug substance to support US trials+other countries+ recently successf. completed QPaudit which allows internally produc. drug substance to be used in support o clinic programs in EU/UK"
X Link 2024-11-26T21:13Z [----] followers, [----] engagements

"$ARWR Update SI"
X Link 2024-11-26T21:38Z [----] followers, [---] engagements

"$ARWR ZODASIRAN alive"
X Link 2024-11-26T21:40Z [----] followers, [---] engagements

"$ARWR Happy to see CVOT pushed back till more capital is available. TRiM platform machine is working hard to push more new candidates in clinic"
X Link 2024-11-26T21:59Z [----] followers, [----] engagements

"$ARWR Capital available [---] billion Cash burn planned for [----] is [---] million. Cash at the end of 2025: 1billion 💰💰"
X Link 2024-11-26T22:10Z [----] followers, [---] engagements

"$ARWR $SRPT My conclusions about risks and chances Summary of Programs under License and Collaboration Agreement Clinical Stage ARO-DUX4 which is designed to target the gene that encodes the DUX4 protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy type [--] currently dosing patients in a Phase 1/2 clinical study. ARO-DM1 which is designed to reduce expression of the dystrophia myotonica protein kinase or DMPK gene in skeletal muscle as a potential treatment for patients with type [--] myotonic dystrophy currently dosing patients in a Phase 1/2 clinical study."
X Link 2024-11-27T20:14Z [----] followers, [----] engagements

"$ARWR More good News from PlozaSiran at AHA and TRIG-Forum More and more evidence that PlozaSiran will be a blockbuster drug. CEO: once in a lifetime opportunity https://www.triglycerideforum.org https://www.triglycerideforum.org"
X Link 2024-11-28T11:29Z [----] followers, [----] engagements

"$ARWR Busy 2weeks Arrowhead Pharmaceuticals to Participate in Upcoming December [----] Conferences https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-december-2024 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-december-2024"
X Link 2024-12-02T12:43Z [----] followers, [---] engagements

"$ARWR: I had some time on my hands and played around with some numbers after the great $SRPT - $ARWR deal I know it's very optimistic and certainly has some small errors but it's only about the macro and not the micro picture. CRAZY Numbers A lot of work for the Sarepta guys @ArrowheadPharma"
X Link 2024-12-05T11:23Z [----] followers, [---] engagements

"$ARWR Exactly and let's keep in mind that INHBE is a liver target candidate. The TRiM liver platform is x time successfully proven (AAT OlpaSiran PlozaSiran and ZodaSiran) Clinical results were even better than pre clinical results So I expect the same for INHBE. ALK7 is targeting adipose tissue and James Hamilton said on one of the last CC that adipose tissue "acts " like the liver tissue. Easy to target with RNAi Can't wait to see trial results in 2025"
X Link 2024-12-09T09:57Z [----] followers, [---] engagements

"$ARWR Developing siRNA for Neurodegenerative Diseases with very nice overview about RNAi and capabilities of TRiM platform https://ir.arrowheadpharma.com/static-files/af976827-088e-4926-912d-b6ca99422187 https://ir.arrowheadpharma.com/static-files/af976827-088e-4926-912d-b6ca99422187"
X Link 2024-12-11T07:31Z [----] followers, [---] engagements

"$ARWR Title: PALISADE: A Phase [--] Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP) The APA/JPS/CAP/IAP [----] Joint Meeting Poster link: https://ir.arrowheadpharma.com/static-files/18ed5e0f-61dc-4af6-81e3-bfd9ce021fde https://ir.arrowheadpharma.com/static-files/18ed5e0f-61dc-4af6-81e3-bfd9ce021fde"
X Link 2024-12-11T07:42Z [----] followers, [---] engagements

"$ARWR 21st Global CVCT Forum Title: A Randomized Placebo-Controlled Phase [--] Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome Data from subjects in an open-label extension trial - a Glimpse into [--] months results Presentation link: https://ir.arrowheadpharma.com/static-files/60c92ea0-beac-4d0b-9f25-8bfaa56179d5 https://ir.arrowheadpharma.com/static-files/60c92ea0-beac-4d0b-9f25-8bfaa56179d5"
X Link 2024-12-11T07:50Z [----] followers, [---] engagements

"$ARWR Conclutions:"
X Link 2024-12-11T09:05Z [----] followers, [----] engagements

"$ARWR Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-interim-clinical-data-aro-cfb https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-interim-clinical-data-aro-cfb"
X Link 2024-12-11T12:32Z [----] followers, [----] engagements

"$ARWR James Hamilton M.D. MBA Chief of Discovery and Translational Medicine at Arrowhead. ARO-CFB also demonstrated dramatic reductions in measures of alternative complement pathway activation with mean reductions at or approaching 100% in AH50 and Wieslab AP at multiple dose levels. These interim results in healthy volunteers give us confidence in the potential of ARO-CFB as we seek to complete Part [--] of the study over the coming months and subsequently look ahead to Part [--] of the study in patients with immunoglobulin A nephropathy which is the most common glomerular disease worldwide"
X Link 2024-12-11T12:34Z [----] followers, [---] engagements

"The Swiss National Bank is lowering interest rates to 0.5% Inflation in Switzerland in November [----] was 0.7% compared to the same month last year. We live in the best country in the world bc we are not part of the EU but independent"
X Link 2024-12-12T09:21Z [----] followers, [---] engagements

"$ARWR PALISADE: A Phase [--] Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute https://ir.arrowheadpharma.com/static-files/57ab3dd8-1748-4a20-9c61-6b4ec05bac32 https://ir.arrowheadpharma.com/static-files/57ab3dd8-1748-4a20-9c61-6b4ec05bac32"
X Link 2024-12-13T15:47Z [----] followers, [---] engagements

"$ARWR And here the poster. https://ir.arrowheadpharma.com/static-files/575f46c5-a803-4c43-93a1-4497170d999c https://ir.arrowheadpharma.com/static-files/575f46c5-a803-4c43-93a1-4497170d999c"
X Link 2024-12-13T15:48Z [----] followers, [---] engagements

"$ARWR Conclusions"
X Link 2024-12-13T15:51Z [----] followers, [----] engagements

"@BioBoyScout Ions without AP reduction label too $ARWR PlozaSiran had statistically significant AP reduction of 83%"
X Link 2024-12-20T14:21Z [----] followers, [---] engagements

"$ARWR Some People have questioned the manufacturing and labor facility at Verona. CEO just perfectly planned it In December [----] the facility is planned to be ready and certified. Thx - again and again - to coldlander at discord: "scheduled to allow for the manufacture of GMP drug substance at the facility which is currently anticipated to begin by December 2024." This facility could turn into a future powerhouse for $ARWR in the light of RNAi future. #AMGN #Novartis et. al. CEO is a visionary"
X Link 2024-12-22T21:25Z [----] followers, [----] engagements

"@pawcio2009 Happy new year to you and your family Thx for your work for the biotech community thx for your daily comments thx for your free honest and - politically - "incorrect" comments Love it"
X Link 2025-01-01T22:25Z [----] followers, [---] engagements

"$ARWR PlozaSiran: Assuming company filed for geno- AND phenotype FCS patients and NDA is accepted in a few days. Does this mean that FDA is ready to approve PlozaSiran for both patient population in Q2/2025 PlozaSiran did meet all endpoint's in phase [--] Incl. statistical reduction of acute pancreatitis of 83% After IONS inferior drug olezarsen (branded as Tryngolza) approval a few days ago approval of PlozaSiran is a no brainer. So the patient population for ARWR should be at least 10x the patient population of IONS IONS extreme price tag is $595'000"
X Link 2025-01-04T21:44Z [----] followers, [----] engagements

"$ARWR I may be wrong but IONS price tag of $595'000 for only genetic confirmed FCS patients without AP label is way too high. If you're the only seller of a new drug against FCS price might be OK. But with $ARWR superior drug (AP label dosing interval less drug more knock down better safety profile and maybe cheaper) coming on the market in just a few months patients and doctors may wait for PlozaSiran - I would wait for sure"
X Link 2025-01-05T11:14Z [----] followers, [---] engagements

"$ARWR Genetic confirmed Familial chylomicronemia syndrome (FCS) has an estimated prevalence of 1/300000 (ranging from 1/100000 to 1/1000000 in Europe and North America). Let's take one third of world's population [---] billion. That will give around [----] patients. Clinically confirmed - phenotype - patients are around tenfold more. Let's assume we get [--] % of genotype FCS patients and [--] % of phenotype FCS patients. Genotype is ultra orphan so price could be $450'000. Phenotype is orphan price could be $100'000. Results: Genotype: $1124955000 Phenotype: $1'666'000'000 This is just playing around"
X Link 2025-01-05T20:22Z [----] followers, [---] engagements

"$ARWR Don't forget that Severe hypercholesterolemia often defined as a LDL-C [---] mmol/L (193 mg/dL) confers 5-fold increased risk of developing ASCVD and is considered an indication for statin therapy in many national and international guidelines. Severe hypercholesterolemia affects 5% of the global population. Our [--] year phase [--] trial is almost fully enrolled. Readout in first have of [----]. sNDA soon afterwards"
X Link 2025-01-05T20:43Z [----] followers, [---] engagements

"$ARWR YES FDA accepts our first NDA Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome We would like to thank all Arrowhead employees and the investigators patients and caregivers who contributed to the PALISADE Phase [--] study of plozasiran in patients with genetically confirmed or clinically diagnosed FCS said Chris Anzalone Ph.D. President and CEO at Arrowhead. Plozasiran has achieved promising and consistent results in various patient populations representing multiple points on the spectrum"
X Link 2025-01-17T22:41Z [----] followers, [----] engagements

"GREAT deal between $ARWR and $SRPT is closed. Whats now (CEO at last CC): Now feel like all the pieces are in place to accelerate growth. We are confident that we will be ready for our potential first commercial launch in [----] provided we receive positive FDA approval. Strategy Balance sheet: See pinned tweet Cash runway extends into [----]. We will end CY25 with approx. $1.5 billion cash. In cardiometabolic area we're focusing resources (75%) as following: PlozaSiran is rapidly progressing toward commercial stage. NDA FDA accepted; PDUFA Nov. 18th We've begun leveraging outsourced resources"
X Link 2025-02-07T11:32Z [----] followers, [----] engagements

"@biomannn @Varro_Analytics TRiM their RNAi platform was introduced in [----] only. Now we have our first NDA of several more to come in coming years. This tells me that this company is becoming a big biotech company. Bigger than alny $ARWR"
X Link 2025-02-08T21:08Z [----] followers, [---] engagements

"$ARWR Confirmation💪💰💪💰 Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics Summary Financial Terms Upon closing Arrowhead receives a $500 millionupfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share. Arrowhead will also receive $250 million to be paid in annual installments of $50 million over [--] years. Arrowhead also has the potential to receive $300 million in near-term payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study of"
X Link 2025-02-10T14:07Z [----] followers, [----] engagements

"$ARWR JUST WOW Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity James Hamilton M.D. MBA Chief Medical Officer and Head of R&D. In preclinical studies in rodents and non-human primates ARO-ALK7 demonstrated dose-dependent and durable reductions in ALK7 mRNA expression in adipose tissue. Pharmacological studies in diet-induced obese mouse models demonstrate that ALK7 silencing in adipose tissue led to improved body composition with an approximate 50% reduction in fat mass with preservation of lean mass. Furthermore co-treatment of tirzepatide a GLP-1/GIP"
X Link 2025-02-25T12:36Z [----] followers, [----] engagements

"@yaireinhorn $ARWR has no RNA editing candidate We are leading the RNAi extra hepatic field and we have a best in class RNAi platform"
X Link 2025-03-17T20:15Z [----] followers, [---] engagements

"After today's SRPT disclosure of a patient's death on their gene therapy Elevidys I know why I like my RNAi platform company $ARWR so much RNAi is a natural occurring process in our body and therefore much lesser risky than a gene therapy. If there is a problem with RNAi - just stop taking the drug. I think also the market is looking at it that way. Sarepta's guidance for 2025: Doug Ingram president and chief executive officerSarepta Therapeutics. In [----] we intend to capitalize on our [----] achievements. In addition to [----] net product revenue guidance of$2.9 billionto$3.1 billion"
X Link 2025-03-18T19:44Z [----] followers, [----] engagements

"$ARWR Results from our annual meeting"
X Link 2025-03-19T10:26Z [----] followers, [---] engagements

"@ej23ny @BowTiedBiotech $ARWR AADT liver population is small Look at these numbers Big market Thanks to @BioBoyScout"
X Link 2025-03-19T11:13Z [----] followers, [---] engagements

"RNAi $ARWR $ALNY Label: https://t.co/dDBqG08LJN $ALNY Label: https://t.co/dDBqG08LJN"
X Link 2025-03-20T22:33Z [----] followers, [----] engagements

"$ARWR Market turmoil Irrational exaggeration in both directions Let's just keep cool and enjoy the last presentation about blockbuster PlozaSiran (Shasta [--] Muir) at: The American College of Cardiology (ACC) [----] March 29-2025 Chicago Illinois Turmoil at the new FDA bc of DOGE Not me I'm very optimistic that we will get our approval before PDUFA date November [--] [----] There are so many ppl working at the FDA just waiting to prove their efficiency and competence to the new administration"
X Link 2025-04-08T14:54Z [----] followers, [----] engagements

"AVORO is heavy invested in $ARWR Really well done. @gline https://t.co/QyZXfaY3LJ Really well done. @gline https://t.co/QyZXfaY3LJ"
X Link 2025-04-10T19:50Z [----] followers, [----] engagements

"$ARWR PASADENA Calif.--(BUSINESS WIRE)--Apr. [--] 2025-- Arrowhead Pharmaceuticals Inc.(NASDAQ: ARWR) today announced that effective May [--] [----] Arrowheads Chief Financial Officer Ken Myszkowski will retire after [--] years of service to the company and will be succeeded by Daniel Apel who has been appointed as the companys new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. Mr. Apel joins the company from Walgreens Boots Alliance where he served as Global Head of Financial Planning and Analysis from 2019"
X Link 2025-04-15T20:08Z [----] followers, [----] engagements

"$ARWR Very nice new Corporate Presentation P121687_Corporate Presentation March [----] Draft1.0 eslide version"
X Link 2025-04-16T11:53Z [----] followers, [----] engagements

"$ARWR https://www.youtube.com/@RNAiRev-q1h4v https://www.youtube.com/@RNAiRev-q1h4v"
X Link 2025-04-21T19:21Z [----] followers, [---] engagements

"$ARWR What could be the impacts from a new and faster FDA What kind of drug processes could be streamlined What's implications has the right to try ARWR with their RNAi TRiM platforms has the potential to treat multiple unmet medical needs with different drug candidates. Let's just take PlozaSiran as example. For me approval of the NDA with PDUFA date Nov 18/25 for FCS patients is a given. 1) If patients get the right to try our very safe and potent drug why do we have to wait till approval in November 2) What's the impact on labeling (AP reduction genetically confirmed and clinically"
X Link 2025-04-22T09:34Z [----] followers, [----] engagements

"$ARWR AI generated video about ARORAGE https://youtu.be/dn1M84Uudpc https://youtu.be/dn1M84Uudpc"
X Link 2025-04-22T11:47Z [----] followers, [---] engagements

"$ARWR Inclisiran (Leqvio) a potent cholesterol-lowering agent byinhibiting PCSK9using siRNA. The first approved siRNA for lipid management. Look at Novartis and their projected sales in [----] Blockbuster This is the way our drug PlozaSiran will perform at least. Novartis is doing the hard for PlozaSiran in informing doctors payers and patients"
X Link 2025-04-29T07:08Z [----] followers, [----] engagements

"$ARWR Leqvio is a subcutaneous injection about every 3-4 months. The Leqvio price for [--] treatment in the US is about $3000 in Europe around [----] Euro. So with a medium price at around $2500 we get to 100'000 patients. With a growth rate of over 72% per Q we could see over [--] million patients in [----] Our way with PlozaSiran when approved for FCS in [----] and sHTG in 2026"
X Link 2025-04-30T06:05Z [----] followers, [---] engagements

"$ARWR No "expert" or analyst in Europe and Switzerland gave Leqvio Blockbuster potential. Could have been the same for ARWR and PlozaSiran. That view will change soon and fast"
X Link 2025-04-30T20:34Z [----] followers, [---] engagements

"$ARWR Thx to Coldlander on Discord Some - very good - new Data: Here is the EAS poster abstract coming out tomorrow. PALISADE: PLOZASIRAN DECREASES THE RISK OF ACUTE PANCREATITIS (AP) AND MAY IMPROVE QUALITY OF LIFE (QOL) IN FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) Background and Aims FCS causes life-threatening AP and may be due to genetic defects in the enzyme lipoprotein lipase (LPL) which impair the circulatory clearance of chylomicrons (CMs) and TGs. Other clinical manifestations collectively impair QoL. Plozasiran is a siRNA that reduces hepatic apolipoprotein C-III effectively lowering"
X Link 2025-05-06T05:47Z [----] followers, [---] engagements

"$ARWR It's all just noise and Wall Street panic. Dr. Prasad's medical statements cannot be extrapolated into the future. He was an outsider and now he's a responsible insider. He has many new bosses: M. Makary R. Kennedy E. Musk and not to forget President D. Trump. He also cannot ignore patient associations and patient lobbyists. They all have the clear goal of keeping pharma and biotech in the US and ensuring that the approval process in the US is not prolonged. RNAi can cure diseases based on a natural process which has not been possible for many diseases until now. The goal of RNAi is not"
X Link 2025-05-07T10:55Z [----] followers, [---] engagements

"$ARWR ZodaSiran final results GATEWAY are online. https://ir.arrowheadpharma.com/static-files/82cdcdd1-eb04-4074-94f0-3c6265ed76d8 https://ir.arrowheadpharma.com/static-files/82cdcdd1-eb04-4074-94f0-3c6265ed76d8"
X Link 2025-05-07T11:23Z [----] followers, [---] engagements

"$ARWR GREAT to see and hear [--] new appointed top managers from the FDA That's communication with the community that's how to do it They sure will shorten the trial and NDA reviews by maintaining safety rules. As I said Wall-street has panicked for nothing. These people are very good for the biotech world. PlozaSiran is on their table for NDA review. @ArrowheadPharma FDA Commissioner Makary sits down for a conversation with the newly appointed director of the Center for Biologics Evaluation and Research (CBER) Dr. Vinayak Vinay Kashyap Prasad and Sanjula Jain-Nagpal Associate Director of Policy"
X Link 2025-05-09T05:11Z [----] followers, [---] engagements

"$ARWR What could be the consequences of this order Companies will manufacture and sell their drugs only in the US"
X Link 2025-05-12T06:34Z [----] followers, [---] engagements

"$ARWR I really did like the reporting income from SRPT partnership in this quarter much better than prorating it over time. Market is at the stage where good news are immediately rewarded and bad news punished accordingly. Till today they never reported such a big cash inflow in ONE Q. For me this is a sign of strength bc management knows more than we do. In the remaining year we can see some other - non dilutive capita e.g.: full enrollment FaziSiran and OlpaSiran MS SRPT DM1 $50 million annual MS SRPT NEW partnership. All together more than $800 million"
X Link 2025-05-13T08:42Z [----] followers, [---] engagements

"$ARWR [--] new Poster from: American Thoracic Society International Conference (ATS 2025) May [--] - May [--] [----] Title: Dual Silencing of Interleukin [--] (IL33) And Thymic Stromal Lymphopoietin Protein (TSLP) With Lung-targeted RNA Interference Molecules Suppresses Pulmonary Allergic Inflammation Title: RAGE Silencing via Inhaled Epithelium Targeted siRNA Mitigates Neutrophilic Inflammation in Rat Models of COPD and ARDS Title: RAGE Haplodeficient Mice are Partially Protected From Allergen Induced Type [--] Inflammation"
X Link 2025-05-18T19:53Z [----] followers, [----] engagements

"$ARWR TRiM Platform for Delivery of RNAi Therapeutics to the Central Nervous System via Subcutaneous Administration We are the RNAi innovation leader for sure https://ir.arrowheadpharma.com/static-files/c24adf87-2bec-4068-9d55-38da5058c5c9 https://ir.arrowheadpharma.com/static-files/c24adf87-2bec-4068-9d55-38da5058c5c9"
X Link 2025-05-22T12:39Z [----] followers, [----] engagements

"$ARWR Title: Development of a Dual Functional RNAi Therapeutic ARO-DIMER-PA for Mixed Hyperlipidemia"
X Link 2025-05-29T13:02Z [----] followers, [----] engagements

"$ARWR SHASTA-5 Rationale and Design: Randomized Double-Blind Placebo-Controlled Study to Evaluate Plozasiran Efficacy and Safety in sHTG at Risk for AP"
X Link 2025-05-30T05:49Z [----] followers, [---] engagements

"$ARWR Plozasiran decreases the risk of Acute Pancreatitis (AP) and may improve Quality of Life (QoL) in Familial Chylomicronemia Syndrome (FCS)"
X Link 2025-05-30T05:54Z [----] followers, [---] engagements

"$ARWR Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia (HTG)"
X Link 2025-05-30T05:57Z [----] followers, [---] engagements

"Philipp Hildebrand Vice Chairman BlackRock Member of the Global Executive Committee of BlackRock is leading the BlackRock Investment Institute (BII) and a former President of the Swiss National Bank is a $ARWR shareholder"
X Link 2025-05-30T20:23Z [----] followers, [---] engagements

"$ARWR Nice chatting with Bruce Given. He said he never understood why BP did go for so long with ASO's . BP's now turning - back - to siRNA's He expects more Business Development deals for us $arwr Jefferies Global Healthcare Conference June 4-5 [----] Type: Fireside Chat Presentation Date/Time: June [--] [----] 9:20 a.m. EDT 46th Annual Goldman Sachs Global Healthcare Conference June 9-11 [----] Type: Fireside Chat Presentation Date/Time: June [--] [----] 2:00 p.m. $arwr Jefferies Global Healthcare Conference June 4-5 [----] Type: Fireside Chat Presentation Date/Time: June [--] [----] 9:20 a.m. EDT 46th Annual"
X Link 2025-06-04T14:29Z [----] followers, [----] engagements

"$ARWR Analysis by grok - part [--] Otsuka Pharmaceuticals: Sibeprenlimab Mechanism: Sibeprenlimab is a monoclonal antibody that selectively blocks the APRIL protein which plays a key role in IgAN by lowering IgA levels. Dosing: Specific dosing details are not provided in the available data but it is administered to achieve a sustained effect over [--] months in the Phase [--] trial. Efficacy: In a Phase [--] trial sibeprenlimab reduced proteinuria by 50.2% after [--] months compared to a 2.1% increase in the placebo group resulting in a placebo-adjusted reduction of 51.2%. This is a stronger numerical"
X Link 2025-06-08T07:43Z [----] followers, [---] engagements

"$ARWR Analysis by grok - part [--] Conclusion ARO-C3 shows promising results with a 41% proteinuria reduction after only three [---] mg doses over [--] months a relatively low dose and infrequent regimen. Its complement-targeting mechanism is distinct and its safety profile is favorable. However its efficacy is slightly lower than competitors in the short term and longer-term data are needed. Sibeprenlimab leads with a 51.2% reduction at [--] months supported by FDA Priority Review but its dosing frequency is likely higher than ARO-C3s. Atacicept is close to ARO-C3 with a 42% reduction and may have a"
X Link 2025-06-08T07:45Z [----] followers, [---] engagements

"$ARWR My own conclusion With AROC3 we have a very safe and much better tolerated candidate. RNAi is a much smoother MOA than other candidates. Also AROC3 not only has positive reduction in proteinuria but also reduced C3 levels by 87% AH50 by 76% and Wieslab AP by 89% indicating strong inhibition of the alternative complement pathway. We don't know the dose regime of the other two competitors I'm guessing it's MUCH higher. Partnership soon"
X Link 2025-06-08T07:57Z [----] followers, [---] engagements

"$ARWR PlozaSiran ZodaSiran OlpaSiran Imagine a room full of your closest friends and family. The odds are that heart disease will affect at least one of them. Heart disease is the leading cause of death for both men and women in the United States claiming a life every [--] seconds. For decades we have been told https://t.co/8UyYbi9mZT Imagine a room full of your closest friends and family. The odds are that heart disease will affect at least one of them. Heart disease is the leading cause of death for both men and women in the United States claiming a life every [--] seconds. For decades we have"
X Link 2025-06-11T13:07Z [----] followers, [----] engagements

"$ARWR Unfortunately I was right about sarepta and their DMD drug. Yes they treated over [---] patients but [--] deaths - [----] % - is maybe too much. What will be their revenues in the future Does the FDA will keep Elevidys on the market How many parents will keep their kids drug Efficacy In summary Elevidys offers functional benefits and disease stabilization for some DMD patients particularly younger ambulatory ones but its efficacy is inconsistent and severe liver risks especially in non-ambulatory patients have prompted safety updates. Ongoing trials and enhanced safety measures aim to clarify"
X Link 2025-06-15T19:20Z [----] followers, [----] engagements

"$ARWR Thx to sarepta for $1 billion cash infusion"
X Link 2025-06-15T19:38Z [----] followers, [----] engagements

"@BioMan944918473 Not really much: Sarepta Therapeutics had approximately $647 million in cash cash equivalents restricted cash and investments as of the end of the first quarter of [----] (March [--] 2025)"
X Link 2025-06-15T21:10Z [----] followers, [---] engagements

"$ARWR congrats Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3 SHASTA-4 and MUIR-3 Phase [--] Studies of Plozasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-completes-enrollment-shasta-3-shasta-4 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-completes-enrollment-shasta-3-shasta-4"
X Link 2025-06-23T11:36Z [----] followers, [----] engagements

"$ARWR CEO: "Enrollment complete in the summer" PROMISE kept at the first day of the summer"
X Link 2025-06-23T11:41Z [----] followers, [---] engagements

"@Biohazard3737 Next thing will be a restructuring and a 30% workforce reduction. Sad for my company ARWR"
X Link 2025-06-25T19:24Z [----] followers, [---] engagements

"Comparison ALNY and $ARWR updated slides"
X Link 2025-07-02T09:02Z [----] followers, [----] engagements

"$ARWR Just in case you didn't read the whole PR let's recap it here: ARWR said: "Should Sarepta fail to make either the $100 million or $200 million near-term payment associated with enrollment of ARO-DM1 cohorts Arrowhead would have the right to terminate the agreement with respect to ARO-DM1 and the program and all associated intellectual property would revert back to Arrowhead. Similarly should Sarepta fail to make any development or commercial milestone payment Arrowhead would have the right to terminate the agreement with respect to the asset for which the payment was owed and the"
X Link 2025-07-23T18:57Z [----] followers, [----] engagements

"$ARWR Ionis reports second quarter [----] financial results and highlights progress on key programs - TRYNGOLZA delivers$19 millionin net product sales in the second quarter [----] $19 Million revenue in only [--] and their first quarter sounds very good to me. PlozaSiran will beat that"
X Link 2025-07-30T11:30Z [----] followers, [----] engagements

"$ARWR The US price of tryngolza is around $600'000. So they treated about [--] patients"
X Link 2025-07-30T12:34Z [----] followers, [---] engagements

"$ARWR Is this Partnership an indicator for the next - much bigger - license deal for PlozaSiran outside the US Sanofi would make sense"
X Link 2025-08-01T11:09Z [----] followers, [---] engagements

"$ARWR Just WOW How many potential hypertriglyceridemia patients in greater China AI says: In [----] there were an estimated [-----] million hypertriglyceridemia (HTG) patients in China representing approximately 20.2% of the adult population according to a press release from Edding Pharmaceuticals. This included about [--] million adults with very high triglyceride levels (500 mg/dL). Further details: Prevalence: The prevalence of hypertriglyceridemia in China has been increasing with studies showing it rising from 5.7% to 15.0% between [----] and 2015"
X Link 2025-08-01T11:21Z [----] followers, [----] engagements

"$ARWR CC Q3/25 tonight after market close. A nice surprise would be the announcement of PlozaSiran approval in Greater China for FCS"
X Link 2025-08-07T09:01Z [----] followers, [---] engagements

"@VSimonAbraham We don't know at this moment. Silence from the company. Two possibility's: [--]. Candidates are not as potent as hoped so they canceled aro-rage and -mmp7 [--]. Pulmonary partnership in the works"
X Link 2025-08-12T10:55Z [----] followers, [---] engagements

"$ARWR New PlozaSiran OL data looks great CEO: One drug within a pipeline one in a lifetime opportunity Take this drug and you will feel much better. We're more than ready for Approval in November25 for FCS next [----] for sHTG. https://ir.arrowheadpharma.com/static-files/85178334-9cf1-4b2d-902a-0b766eb133e0 https://ir.arrowheadpharma.com/static-files/85178334-9cf1-4b2d-902a-0b766eb133e0"
X Link 2025-08-30T17:49Z [----] followers, [----] engagements

"$ARWR New ZodaSiran OL data looks great also Look at the remnant cholesterol Down that's were it stays AI says: https://ir.arrowheadpharma.com/static-files/d9630706-0c91-4c68-8332-2e767d022399 https://ir.arrowheadpharma.com/static-files/d9630706-0c91-4c68-8332-2e767d022399"
X Link 2025-08-31T08:41Z [----] followers, [----] engagements

"@ArrowheadPharma @Novartis Congratulations"
X Link 2025-09-02T11:47Z [----] followers, [---] engagements

"$ARWR And again a big player is confirming the RNAi leadership platform TRiM from @ArrowheadPharma"
X Link 2025-09-02T11:55Z [----] followers, [---] engagements

"$ARWR Sorry just can't resist How many ppl were shooting at our CEO to slow the pre clinic and early phase candidates You're just burning cash with it Put all the resources to get [--] candidate finally over the finish line (approval). I'm very happy that he didn't listen to them and followed his initial strategy The cash burning candidates got us to potentially $13 billion partnerships with Novartis and Sarepta and over $1 billion upfront payment in about [--] months F.ing nice Congrats to @ArrowheadPharma CEO Christopher Anzalone"
X Link 2025-09-03T18:56Z [----] followers, [----] engagements

"$ARWR Some slides from today's presentation"
X Link 2025-09-10T11:41Z [----] followers, [---] engagements

"$ARWR Link https://ir.arrowheadpharma.com/static-files/16629e9f-4cbf-4c34-a39d-f64a88f4a6d5 https://ir.arrowheadpharma.com/static-files/16629e9f-4cbf-4c34-a39d-f64a88f4a6d5"
X Link 2025-09-10T11:42Z [----] followers, [---] engagements

"$ARWR The MOA of this molecule (sc) is the reason Novartis just did a big CNS partnership with us. Potential of $2 billion milestone payment with $200 million upfront"
X Link 2025-09-10T13:04Z [----] followers, [---] engagements

"$ARWR What kind of a company is $IONS $%#%# Because they know they have an inferior drug they try it that way Awful for them"
X Link 2025-09-11T11:50Z [----] followers, [----] engagements

"@seizethemoney $ARWR Nothing for the moment they are just shouting at each other in the public"
X Link 2025-09-11T12:16Z [----] followers, [---] engagements

"$ARWR Next event not in September-PR included with surprise potential - new data"
X Link 2025-09-17T05:37Z [----] followers, [---] engagements

"$ARWR AGAIN Lawsuits dismissed http://shareholdersfoundation.com/case/arrowhead-research-corporation-nasdaq-arwr-investor-securities-class-action-lawsuit-10102014 http://shareholdersfoundation.com/case/arrowhead-research-corporation-nasdaq-arwr-investor-securities-class-action-lawsuit-10102014"
X Link 2018-04-02T07:24Z [----] followers, [--] engagements

"@truthtracer $ARWR Could they even have some of the old arc520/521 patients as patients in AROHBV trial @michael007here"
X Link 2018-05-13T19:35Z [----] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing